<DOC>
	<DOCNO>NCT00346242</DOCNO>
	<brief_summary>The evaluation efficacy perform laboratory monitoring bone density resorption marker clinical monitor bone density improvement . This prospective , randomize , parallel group , single blind study one year treatment zoledronic acid every 6 month compare one year treatment zoledronic acid every 3 month placebo every 3 month patient hemoglobin syndrome risk skeletal complication .</brief_summary>
	<brief_title>Evaluation Efficacy Zoledronic Acid Patients With Haemoglobin Syndromes ( Thalassemia Sicle Cell Anaemia ) Risk Skeletal Events</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients thalassaemia sickle cell anaemia bone density , zscores &lt; 1.5 , least one examine sit Normal renal function . Urea creatinine exceed &gt; 2fold upper limit normal ( &lt; 2 x ULN ) . Other protocoldefined inclusion / exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>thalassemia</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>skeletal event</keyword>
</DOC>